
EMEA Point-Of-Care Diagnostics Market Growth, Size, Trends Analysis - By Product, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Description
EMEA Point-Of-Care Diagnostics Market Introduction and Overview
According to SPER market research, ‘EMEA Point-Of-Care Diagnostics Market Size- By Product, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the EMEA Point-Of-Care Diagnostics Market is predicted to reach 25.81 billion by 2034 with a CAGR of 6.43%.
A diagnostic kit is a collection of equipment and reagents designed to detect, analyse, or monitor certain health problems, infections, or diseases in patients. These diagnostics provide quick responses and allow doctors to make timely decisions without the need for centralised laboratory equipment. PoC diagnostics have a wide range of applications, including glucose monitoring, infectious disease detection, cardiac indicators, and pregnancy testing.
Restraints:The EMEA point-of-care diagnostics market has several obstacles that prevent it from realising its full potential. A fragmented regulatory environment across countries increases approval time and complicates compliance. The high initial prices of current PoC devices impede adoption, particularly in resource-constrained environments. Data privacy concerns, particularly under legislation like GDPR, pose hurdles for linked and digital testing systems.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Product, By End User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Abbott, BD (Becton Dickinson), BIOMÉRIEUX, Danaher Corporation, F. Hoffmann-La Roche Ltd, Nova Biomedical, QIAGEN, Siemens Healthcare Private Limited, Trividia Health, Inc, Werfen.
EMEA Point-Of-Care Diagnostics Market Segmentation:
By Product: Based on the product, EMEA Point-Of-Care Diagnostics Market is segmented as; Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Vikram, Cardiac Markers, Thyroid Stimulating Hormone, Haematology, Primary Care Systems.
By End User:
Based on the End User, EMEA Point-Of-Care Diagnostics Market is segmented as; Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory, Others.
By Region:
This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
According to SPER market research, ‘EMEA Point-Of-Care Diagnostics Market Size- By Product, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the EMEA Point-Of-Care Diagnostics Market is predicted to reach 25.81 billion by 2034 with a CAGR of 6.43%.
A diagnostic kit is a collection of equipment and reagents designed to detect, analyse, or monitor certain health problems, infections, or diseases in patients. These diagnostics provide quick responses and allow doctors to make timely decisions without the need for centralised laboratory equipment. PoC diagnostics have a wide range of applications, including glucose monitoring, infectious disease detection, cardiac indicators, and pregnancy testing.
Restraints:The EMEA point-of-care diagnostics market has several obstacles that prevent it from realising its full potential. A fragmented regulatory environment across countries increases approval time and complicates compliance. The high initial prices of current PoC devices impede adoption, particularly in resource-constrained environments. Data privacy concerns, particularly under legislation like GDPR, pose hurdles for linked and digital testing systems.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Product, By End User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Abbott, BD (Becton Dickinson), BIOMÉRIEUX, Danaher Corporation, F. Hoffmann-La Roche Ltd, Nova Biomedical, QIAGEN, Siemens Healthcare Private Limited, Trividia Health, Inc, Werfen.
EMEA Point-Of-Care Diagnostics Market Segmentation:
By Product: Based on the product, EMEA Point-Of-Care Diagnostics Market is segmented as; Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Vikram, Cardiac Markers, Thyroid Stimulating Hormone, Haematology, Primary Care Systems.
By End User:
Based on the End User, EMEA Point-Of-Care Diagnostics Market is segmented as; Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory, Others.
By Region:
This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
161 Pages
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. EMEA Point-Of-Care Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in EMEA Point-Of-Care Diagnostics Market
- 7. EMEA Point-Of-Care Diagnostics Market by Product (USD Million) 2021-2034
- 7.1. Glucose Testing
- 7.2. Hb1Ac Testing
- 7.3. Coagulation Testing
- 7.4. Fertility/Pregnancy
- 7.5. Vikram
- 7.6. Cardiac Markers
- 7.7. Thyroid Stimulating Hormone
- 7.8. Haematology
- 7.9. Primary Care Systems
- 8. EMEA Point-Of-Care Diagnostics Market by End UseR (USD Million) 2021-2034
- 8.1. Hospitals
- 8.2. Home
- 8.3. Assisted Living Healthcare Facilities
- 8.4. Laboratory
- 8.5. Others
- 9. EMEA Point-Of-Care Diagnostics Market (USD Million) 2021-2034
- 9.1. EMEA Point-Of-Care Diagnostics Market Size and Market Share
- 10. EMEA Point-Of-Care Diagnostics Market by Region, (USD Million) 2021-2034
- 10.1. Europe
- 10.1.1. UK
- 10.1.2. Germany
- 10.1.3. France
- 10.1.4. Italy
- 10.1.5. Spain
- 10.1.6. Denmark
- 10.1.7. Sweden
- 10.1.8. Norway
- 10.2. Middle East and Africa
- 10.2.1. South Africa
- 10.2.2. UAE
- 10.2.3. Saudi Arabia
- 10.2.4. Kuwait
- 11. Company Profile
- 11.1. Abbott
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
- 11.2. BD (Becton Dickinson)
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
- 11.3. BIOMÉRIEUX
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
- 11.4. Danaher Corporation
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
- 11.5. F. Hoffmann-La Roche Ltd
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
- 11.6. Nova Biomedical
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
- 11.7. QIAGEN
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
- 11.8. Siemens Healthcare Private Limited
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
- 11.9. Trividia Health, Inc
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
- 11.10. Werfen
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
- 11.11. Others
- 12. Conclusion
- 13. List of Abbreviations
- 14. Reference Links
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.